Enanta Pharma (ENTA) Tops Q3 EPS by 4c. Revs Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Enanta Pharmaceuticals (ENTA) PT Raised to $38 at JPMorgan
August 8, 2017 8:45 AM EDTJPMorgan raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $38.00 (from $32.00) while maintaining a Overweight rating.
... MoreEnanta Pharmaceuticals (ENTA) PT Raised to $36 at Baird; Remains Sidelined
August 8, 2017 7:19 AM EDTBaird raised its price target on Enanta Pharmaceuticals (NASDAQ: ENTA) to $36.00 (from $27.00) while maintaining a Neutral rating following the company's 3Q. AbbVie's reported sales of $225M for Viekira were largely in line with estimates. Enanta earned $7.5M in royalty revenue on these sales, versus... More
